Table 1.

Comparison of clinical characteristics between PM/DM-ILD patients who were responsive and non-responsive to TPE.

Variables	Responsive group (n = 11)	Non-responsive group (n = 7)	P-value
Sex, male/female, n (%)	3/8 (27.3/72.7)	3/4 (42.9/57.1)	0.627
Age, years, mean ± SEM	55.70 ± 11.08	52.71 ± 11.46	0.540
DISEASE DURATION, WEEKS, MEDIAN (RANGE)
at ILD diagnosis	3.0 (1–4)	3.2 (1.57–5.71)	0.328
at PM/DM/CADM diagnosis	13 (2.43–96)	6.86 (4–528)	0.536
IIM TYPE, n (%)
PM/DM	2/3 (18.2/27.3)	0/2 (0/28.6)	0.952
CADM	6 (54.5)	5 (71.4)	0.637
CLINICAL SYMPTOM, n (%)
Arthritis/arthralgia	4 (36.4)	1 (14.3)	0.596
Skin rash	9 (81.8)	6 (85.7)	1.000
Fever	3 (27.3)	2 (28.6)	1.000
Cough	4 (36.4)	3 (42.9)	1.000
Dyspnea on exertion	9 (81.8)	6 (85.7)	1.000
Dysphagia	3 (27.3)	1 (14.3)	1.000
Muscle weakness/myalgia	5 (45.5)	1 (14.3)	0.316
Subcutaneous/mediastinal emphysema n (%)	2 (18.2)*	6 (85.7)	0.013
APACHE II Score, median (range)	17 (11–24)	18.5 (15–31)	0.126
P/F ratio	218.8 ± 13.38	173.3 ± 21.38	0.074
THERAPY, n (%)
High-dose steroids	11 (100)	7 (100)	NA
Cyclosporine A	8 (72.7)	5 (71.4)	1.000
Cyclophosphamide	6 (54.5)	2 (28.6)	0.367
Intravenous immunoglobulin G	6 (54.5)	5 (71.4)	0.637
Hydroxychloroquine	1 (9.1)	1 (14.3)	1.000
Methotrexate	1 (9.1)	0	0.611
Thalidomide	2 (18.2)	0	0.137
Total dosage of MP before TPE, mg (mean ± SEM)	460.9 ± 49.88	341.4 ± 61.81	0.153
Duration of MP use before TPE, days (mean ± SEM)	6.6 ± 0.3	6.4 ± 0.4	0.676
PLASMA EXCHANGE
Times, median (range)	5 (4–24)	6 (4–10)	0.724
Plasma amount, mL, median (range)	3,000 (2,500–3,000)	3,000 (2,500–3,000)	0.724
Use of ventilator, n (%)	4 (36.4)	6 (85.7)	0.066

ILD, Interstitial lung disease; PM, polymyositis; DM, dermatomyositis; CADM, clinically amyopathic dermatomyositis; IIM, idiopathic inflammatory myopathy; SEM, standard error of mean; TPE, therapeutic plasma-exchange; APACHE II, Acute Physiology and Chronic Health Evaluation; MP, methylprednisolone; P/F, arterial partial pressure of oxygen /fraction of inspired oxygen.

^*p < 0.05.